Variant · Snv

KRAS G13

CI-VAR-00001626Explore in graph →p.Gly13AspNM_004985.5:c.38G>AClinVar 12580 CIViC 80 rs112445441

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Colorectal Adenocarcinoma2
KRAS G12 OR KRAS G13 OR KRAS Q61	(prognostic)	Prognostic	B	Supports Poor Outcome	3	submitted	EID11056 The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC) PMID 21641636 · Maughan et al., 2011 · Open in CIViC	civic
KRAS G12 OR KRAS G13 OR KRAS Q61	Cetuximab + ChemotherapyCombination	Predictive	B	Does Not Support Sensitivity Response	4	submitted	EID11055 The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC) PMID 21641636 ·

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
12580	Pathogenic	criteria provided, multiple submitters, no conflicts	2	Breast adenocarcinoma; Non-small cell lung carcinoma; Juvenile myelomonocytic leukemia; OCULOECTODERMAL SYNDROME, SOMATIC; Inborn genetic diseases; Nevus sebaceous; RASopathy; Noonan syndrome and Noonan-related syndrome; Encephalocraniocutaneous lipomatosis; KRAS-related disorder; Neoplasm; Melanoma; Acute myeloid leukemia; Malignant tumor of urinary bladder; Cervical cancer; Familial pancreatic carcinoma; Adenocarcinoma of the large intestine; Embryonal rhabdomyosarcoma; Diffuse midline glioma, H3 K27M-mutant; Colorectal cancer; RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER 2, SOMATIC